[Evaluation of the effectiveness of monotherapy in the treatment of epilepsy].
On 44 patients undergoing monotherapy, with total plasma levels of drug therapeutic range, 33 had a reduction of the frequency of seizures, while the remaining 11 were unmodified. There was 90% improvement in Primary Generalized seizures, 73% in Secondary Generalized and 62% in Partial Complex; 27% of PC, 16% of PG and 16% of SG shifted to polytherapy. Considering that monotherapy can be better managed and is less toxic, we can recommend it as first choice treatment in newcomers, as a maintenance therapy, and as treatment of choice for the gradual elimination of therapy.
Brignolio
F
F
Divisione Universitaria di Neurologia, Ospedale S. Luigi Gonzaga, Orbassano, Torino.
Verzè
L
L
Baruchello
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D002220:Carbamazepine / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010634:Phenobarbital / Q000627:therapeutic use*; D010672:Phenytoin / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use*
D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin; D010634:Phenobarbital
Valutazione dell'efficacia della monoterapia nel trattamento dell'epilessia.